Rapport Therapeutics (NASDAQ:RAPP - Get Free Report) will likely be posting its quarterly earnings results before the market opens on Thursday, February 27th. Analysts expect Rapport Therapeutics to post earnings of ($0.62) per share for the quarter.
Rapport Therapeutics Stock Down 2.5 %
Shares of Rapport Therapeutics stock opened at $12.68 on Friday. The stock has a 50 day moving average price of $16.11 and a two-hundred day moving average price of $19.85. Rapport Therapeutics has a 12-month low of $12.09 and a 12-month high of $29.74.
About Rapport Therapeutics
(
Get Free Report)
Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Rapport Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rapport Therapeutics wasn't on the list.
While Rapport Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
